FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002). Background: Immune checkpoint inhibitors (ICIs) relieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results